… However, patients with homozygous inactivating mutations of … effects on tumor control,
preclinical studies to define risks for … as radiosensitizing or chemosensitizing agents. Foremost …

… We looked for all clinical or pre-clinical studies related … chemosensitizer depending on
MGMT status stay debated [40, 56–58]even if some phase II-III clinical trials recruits only patients …

… In vitro studies using the cell lines A2780 (human ovarian cancer cells derived from untreated
patient tumor tissue), SKOV3 (ovarian adenocarcinoma resistant to multiple substances, …

… to evaluate in pre-clinical models whether addition of vorinostat could potentiate the
chemosensitizing effect … In further pre-clinical studies, we demonstrated that DNMTI is likely the …

… and survival rate of patients. The identification of unconventional chemosensitizing agents is
therefore an … In preclinical trials resveratrol has shown immense potential in the cancer field, …

… Nonetheless, further studies of a combination of … of patients diagnosed with different types
of cancer that may plausibly lead to significant advancement in therapeutic benefit to patients …

… Thus, for patients with ovarian cancer, ARS4 is a promising chemotherapeutic agent. … Based
on its preclinical efficacy and safety, we conclude that the ARS-melphalan conjugate ARS4 …

… of the progression from preclinical studies to clinical trials. In … in local control as well as
chemosensitization to assist in the … toxic treatment outcomes for patients and enhance the return-…

… Preclinical studies had demonstrated synergistic effects of … revealed PR in 10/19 patients
with advanced stage NSCLC; these … evaluating patients with stage IIIB/IV NSCLC, a total of 62 …

… in the cancer patients is necessary. … studies, but regarding the chemosensitizing effects of
melatonin on cancer cells, more detailed studies should be carried out in both preclinical and …